Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases

Journal of Child Neurology

Volumn 32, Issue 1, 2017, Pages 35-40

  Gofshteyn, Jacqueline S ^a   Wilfong, Angus ^b   Devinsky, Orrin ^c   Bluvstein, Judith ^c   Charuta, Joshi ^d   Ciliberto, Michael A ^d   Laux, Linda ^e   Marsh, Eric D ^a,f  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cannabidiol; febrile infection related epilepsy syndrome (FIRES); pediatric epilepsy; refractory status epilepticus

Indexed keywords

CANNABIDIOL; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYCLOPHOSPHAMIDE; FELBAMATE; IMMUNOGLOBULIN; ISOFLURANE; KETAMINE; LACOSAMIDE; LAMOTRIGINE; LEVETIRACETAM; MIDAZOLAM; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; RITUXIMAB; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; ANTICONVULSIVE AGENT;

ARTICLE; ATAXIA; CHILD; CLINICAL ARTICLE; CORPUS CALLOSUM; DECREASED APPETITE; DIZZINESS; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FEBRILE INFECTION RELATED EPILEPSY SYNDROME; FEMALE; FOCAL MOTOR SEIZURE; HIPPOCAMPAL SCLEROSIS; HUMAN; KETOGENIC DIET; MALE; MULTIPLE ORGAN FAILURE; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; SUPERIOR TEMPORAL SULCUS; TONIC CLONIC SEIZURE; UNCONSCIOUSNESS; VOMITING; WEIGHT REDUCTION; ACUTE DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; DRUG RESISTANT EPILEPSY; EPILEPSY; FEVER; INFECTION; MULTICENTER STUDY; TREATMENT OUTCOME;

ACUTE DISEASE; ANTICONVULSANTS; CANNABIDIOL; CHILD; CHRONIC DISEASE; DRUG RESISTANT EPILEPSY; EPILEPTIC SYNDROMES; FEVER; HUMANS; INFECTION; MALE; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 85006387041     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073816669450     Document Type: Article

References (21)

1. Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011; 52 (11): 1956-1965.
2. Howell KB, Katanyuwong K, Mackay MT, et al. Long-term follow-up of febrile infection-related epilepsy. Epilepsia. 2012; 53 (1): 101-110.
3. Oguni HFY,. Pathogenesis of epilepsy in childhood. Jpn J Psychiatry Neurol. 1986; 40 (3): 293-299.
4. Mikaeloff Y, Jambaqué I, Hertz-Pannier L, et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. Epilepsy Res. 2006; 69 (1): 67-79.
5. Sakuma H, Sugai K SM,. Acute nonparaneoplastic limbic encephalitis in childhood: a case series in Japan. Pediatr Neurol. 2010; 43 (3): 167-172.
6. van Baalen A, Häusler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia. 2010; 51 (7): 1323-1328.
7. Nabbout R, Vezzani A, Dulac O,. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol. 2011; 10 (1): 99-108.
8. Zhonghua Er Ke Za Zhi. Fever-induced refractory epileptic encephalopathy in school-aged children: clinical features and outcome-a multicenter study on 13 children. Collaborative Group for Fever-induced Refractory Epileptic Encephalopathy in School-aged Children. 2010; 50 (8): 575-579.
9. Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia. 2010; 51 (10): 2033-2037.
10. Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): does duration of anesthesia affect outcome? Epilepsia. 2011; 52 (suppl 8): 28-30.
11. Walker MC, White HS,. Disease modification in partial epilepsy. Brain. 2002; 125 (9): 1937-1950.
12. Rantala H, Saukkonen AL, Remes M,. Efficacy of five days' barbiturate anesthesia in the treatment of intractable epilepsies in children. Epilepsia. 1999; 40 (12): 1775-1779.
13. Haginoya K, Munakata M, Kato R, Yokoyama H, Ishizuka M,. Ictal cerebral haemodynamics of childhood epilepsy measured with near-infrared spectrophotometry. Brain. 2002; 125 (9): 1960-1971.
14. Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015; 47: 138-141. doi:10.1016/j.yebeh.2015.04.009.
15. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016; 15 (3): 270-278.
16. Varadkar S, Cross JH,. Rasmussen syndrome and other inflammatory epilepsies. Semin Neurol. 2015; 35 (3): 259-268. doi:10.1055/s-0035-1552921.
17. Kim JA, Yoon JR, Lee EJ, et al. Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. Epilepsia. 2016; 57 (1): 51-58. doi:10.1111/epi.13256.
18. Granja AG, Carrillo-Salinas F, Pagani A, et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J Neuroimmune Pharmacol. 2012; 7 (4): 1002-1016. doi:10.1007/s11481-012-9399-3.
19. Booz GW,. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med. 2011; 51 (5): 1054-1061. doi:10.1016/j.freeradbiomed.2011.01.007.
20. Barichello T, Ceretta RA, Generoso JS, et al. Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur J Pharmacol. 2012; 697 (1-3): 158-164. doi:10.1016/j.ejphar.2012.09.053.
21. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014; 55 (6): 791-802. doi:10.1111/epi.12631.